about
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results.Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.Real-world evaluation of compliance and preference in Alzheimer's disease treatment.Rivastigmine in Parkinson's disease dementia.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Turning principles into practice in Alzheimer's disease.Drug delivery strategies for Alzheimer's disease treatment.Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.Development and validation of a spectrofluorimetric method for the estimation of rivastigmine in formulationsTransdermal patches: the emerging mode of drug delivery system in psychiatry.Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation.Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation.A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.Pharmacological treatment in moderate-to-severe Alzheimer's disease
P2860
Q33596451-0D2BE8F9-A2DF-4C1B-AA7B-EF38C4575CCDQ34327769-C5B07BA1-798A-4286-97A6-7B3094FE6953Q34516224-B1B0E233-CCFF-42A4-A896-F85C2D5D5AA1Q35252005-15977ECD-8308-4A98-BE18-796CC21B8C39Q35539649-65BEE067-65BF-4C20-ADB8-F4A0E8D005FCQ36264977-06E96739-6254-46D0-BAF9-043D5763F436Q37232006-49F5C8FC-FC1A-457E-9C46-51B366C9E6DCQ37325828-3D88FA11-7E24-4743-B77E-59C6F713C50EQ37763287-214D9516-ACB4-4BBE-B822-0C4C4157FFEFQ37851509-A3A3617C-7768-4406-AFCB-E81237034D1DQ39477637-FBBC03A8-6F59-4FC3-B2FE-A9981ACCDF4EQ40431408-5DF9CC26-170B-47B0-A9BF-BB4AC37DA150Q42248837-0DA7F8BE-F9E1-4875-897E-4E12F31E25B1Q44014924-FD2443FB-3504-4DCB-9712-87B41FC62F4DQ45892584-6C245388-D272-45B4-95A9-B7501CD0A920Q48152841-DC86D66A-56A7-4819-8BF8-FF0B7CED5D93Q48439989-5E87CB77-11AB-43C6-BA49-3BC1A5C50846Q50328399-422F934E-D787-4834-9EC5-C4B65BB40E0AQ50780492-6E58DC08-9325-4A68-955D-0CEFCAE406CFQ50799612-7220766F-4D51-4EFA-9C0F-5FC76DBA7F6AQ57529900-E8947402-4A72-43FE-8C6F-C7B54A99E0DF
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pharmacokinetic rationale for the rivastigmine patch.
@ast
Pharmacokinetic rationale for the rivastigmine patch.
@en
Pharmacokinetic rationale for the rivastigmine patch.
@nl
type
label
Pharmacokinetic rationale for the rivastigmine patch.
@ast
Pharmacokinetic rationale for the rivastigmine patch.
@en
Pharmacokinetic rationale for the rivastigmine patch.
@nl
prefLabel
Pharmacokinetic rationale for the rivastigmine patch.
@ast
Pharmacokinetic rationale for the rivastigmine patch.
@en
Pharmacokinetic rationale for the rivastigmine patch.
@nl
P2093
P1433
P1476
Pharmacokinetic rationale for the rivastigmine patch.
@en
P2093
Gary Small
Gilbert Lefèvre
Jeffrey Cummings
Silke Appel-Dingemanse
P356
10.1212/01.WNL.0000281846.40390.50
P407
P433
P577
2007-07-01T00:00:00Z